Absent T Lymphocytes

Search Trials
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Status:
Completed
Last Changed:
Apr 16, 2014
First Changed:
Jun 6, 2003
Disease(s):
Acute Undifferentiated Leukemia
Intervention(s):
allopurinolcyclophosphamidedaunorubicin hydrochloridevincristine sulfatedexamethasoneasparaginasefilgrastimimatinib mesylatemethotrexatecytarabinetrimethoprim-sulfamethoxazolemercaptopurineleucovorin calciumalemtuzumabacyclovirlaboratory biomarker analysispharmacological study
Calaspargase Pegol in Adults With ALL
Status:
Recruiting
Last Changed:
Oct 11, 2021
First Changed:
Mar 26, 2021
Disease(s):
Acute Lymphoblastic Leukemia
Intervention(s):
Calaspargase pegol (S95015)
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Last Changed:
Jun 7, 2021
First Changed:
Jun 29, 2015
Disease(s):
B Acute Lymphoblastic Leukemia
Intervention(s):
Laboratory Biomarker AnalysisPharmacological StudySapanisertib
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Status:
Recruiting
Last Changed:
Jan 6, 2021
First Changed:
Jul 21, 2020
Disease(s):
T Lymphoblastic Leukemia/Lymphoma
Intervention(s):
T cell injection targeting CD7 chimeric antigen receptor
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Status:
Completed
Last Changed:
Dec 15, 2016
First Changed:
Mar 4, 2005
Disease(s):
Chronic Myeloproliferative Disorders
Intervention(s):
alemtuzumabtherapeutic allogeneic lymphocytesfludarabine phosphatemelphalantacrolimusthiotepaperipheral blood stem cell transplantation

Connect. Empower. Inspire.